Endeavor BioMedicines Presents New Clinical Findings From Post Hoc Analysis of Phase 2a Clinical Trial Evaluating ENV-101 in Patients with Idiopathic Pulmonary Fibrosis
SAN DIEGO--(BUSINESS WIRE)-- Endeavor BioMedicines ('Endeavor'), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today presented a post hoc analysis from the completed Phase 2a clinical trial of its lead investigational therapy, ENV-101 (taladegib). Results demonstrated a significant reduction in pulmonary vessel volume, a significant increase in lung volume, and a trend towards reduced lung fibrosis for idiopathic pulmonary fibrosis (IPF) patients treated with ENV-101 for 12 weeks vs. placebo. The analysis utilized Qureight's deep learning-based computed tomography (CT) analytics technologies and was presented in a poster presentation at the American Thoracic Society (ATS) 2025 International Conference.
Lung volume, fibrotic tissue volume and pulmonary vessel volume are all volumetric lung measures that can change during IPF disease progression or in response to treatment. Each measure has been established as an independent predictor of mortality. Deep learning-based quantification of lung volume and pulmonary vascular changes may offer valuable insights that corroborate physiological improvement in lung function and measure treatment outcomes with a greater effect size than forced vital capacity (FVC), the current registrational endpoint in IPF. A new finding from this post hoc analysis demonstrated a significant reduction in pulmonary vessel volume for patients in the ENV-101 treatment arm versus placebo. A reduction in pulmonary vessel volume has been correlated with improved mortality and decreased disease burden. To date, ENV-101 is the only therapeutic that has demonstrated a reduction in pulmonary vessel volume in patients with IPF, providing further evidence that ENV-101 has the potential to reverse disease across multiple measures of IPF.
'These findings provide additional evidence of clinical utility of ENV-101 in patients with IPF marking another step forward in our mission to restore hope and improve lives for those facing this otherwise devastating disease,' said Lisa Lancaster, M.D., Chief Medical Officer, Endeavor BioMedicines. 'We are grateful to the Qureight team for partnering with us on this important analysis.'
The post hoc analysis of the Phase 2a trial was conducted using novel deep learning-based CT analysis technologies developed by Qureight Ltd (Cambridge, UK). Qureight used three deep learning models developed to quantify lung volume (Lung8), pulmonary vessel volume (Vascul8), and fibrosis extent (Fibr8) on the baseline and follow-up CTs of ENV-101 treated and placebo patients (ENV-101 = 16; placebo = 18).
Key Results from the Post Hoc Analysis Presented at ATS 2025
Significant increase in lung volume (Lung8) for patients in the ENV-101 treatment arm vs placebo (placebo: −113.07 mL vs ENV-101: 142.28 mL; p=0.014; effect size=0.87).
Trend towards reduced fibrosis (Fibr8) for ENV-101 treated patients vs placebo (placebo: 1.32pp vs ENV-101: −1.32pp; p=0.063; effect size=−0.64).
Significant reduction in normalized pulmonary vessel volume (Vascul8) for patients in the ENV-101 treatment arm vs placebo (placebo: 0.07pp vs ENV-101: -0.25pp; p=0.0007; effect size=-1.28).
'We are excited to share significant findings from the post hoc analysis of the phase 2a clinical trial of ENV-101, highlighting our pulmonary vessel volume quantification model, Vascul8,' said Simon Walsh, M.D., Ph.D., Chief Scientific Officer, Qureight. 'Using this model, we quantified a significant treatment effect from ENV-101, with a greater effect size than forced vital capacity. Qureight's deep learning-based imaging biomarkers offer distinct advantages by capturing treatment signals from each prognostic compartment of the lung separately, optimizing for precision medicine.'
About the ENV-101 Phase 2a Clinical Trial
Data from the post hoc analysis independently validates and builds upon the previously reported results from the Phase 2a randomized, double-blind, multi-center, placebo-controlled clinical trial of ENV-101 (NCT04968574). In the trial, ENV-101 demonstrated significant improvements in lung function and total lung volume, while also showing a reduction in key measures of lung fibrosis versus placebo with a manageable safety profile.
About the WHISTLE-PF Trial
Endeavor continues to study ENV-101 and has initiated the Phase 2b WHISTLE-PF (W ound-remodeling H edgehog-Inhibitor I LD S tudy T esting L ung Function E ndpoints- PF) clinical trial, a global, randomized, placebo-controlled study evaluating the therapeutic potential of ENV-101 in individuals with IPF (NCT06422884). The WHISTLE-PF trial will evaluate the efficacy of a range of ENV-101 doses through 24 weeks of treatment, characterize the investigational compound's safety, assess its effect on patient reported outcomes and its effects on lung capacity and lung fibrosis as measured by chest HRCT.
About Idiopathic Pulmonary Fibrosis
IPF is a chronic, progressive lung disease that affects more than 150,000 adults in the United States. Although the exact cause of IPF is unknown, various environmental factors can deliver repeated injuries to lung cells that trigger abnormal wound-healing processes and life-threatening lung scarring. IPF is a chronic disease with limited treatment options and a very poor prognosis: the average life expectancy is only three to five years after diagnosis.
About ENV-101
Endeavor BioMedicines' investigational medicine ENV-101 (taladegib) is a Hedgehog signaling pathway inhibitor. By binding to and inhibiting a key receptor in the Hedgehog pathway, ENV-101 stops the abnormal accumulation of the myofibroblasts that cause fibrosis. This may resolve the excessive wound-healing process seen in pulmonary fibrosis, improving lung volume and function.
About Endeavor BioMedicines
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor's lead candidate, ENV-101 (taladegib), is an inhibitor of the Hedgehog signaling pathway in development for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). The company's second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) in development for the treatment of HER3-positive solid tumors. More information is available at www.endeavorbiomedicines.com and on LinkedIn or X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Fairchild Gold Announces Closing of the Second Tranche of Its Previously Announced Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2025) - Fairchild Gold Corp. (TSXV: FAIR) ("Fairchild" or the "Company") is pleased to announce the closing of the second tranche of its non-brokered private placement for gross proceeds of $655,000.08 (the "Offering") on June 6, 2025. In connection with the closing of the Offering, the Company issued 10,916,668 units (the "Units") at a price of $0.06 per Unit. The Company previously closed a first tranche of the Offering on April 22, 2025, for gross proceeds of $810,000, and announced the upsizing of its Offering on May 28, 2025. Each Unit is comprised of one common share (a "Common Share") in the capital of the Company and one common share purchase warrant (a "Warrant"), whereby each whole Warrant shall be convertible into an additional Common Share at an exercise price of $0.15 for a period of sixty (60) months from the date of issuance. The Warrants include an acceleration clause to the effect that if the daily volume weighted average closing price of the common shares on the TSX Venture Exchange is at least $0.50 per Common Share for a period of five (5) consecutive trading days, 12 months after the closing date of the Offering (the "Triggering Event"), the Company may, within 5 days of the Triggering Event, accelerate the expiry date of the Warrants by giving notice thereof to the holders of the Warrants, by way of news release, and in such case the Warrants will expire on the first day that is 10 calendar days after the date on which such notice is given by the Company announcing the Triggering Event. The Offering constitutes a "related party transaction" under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"), as Robert Rosner, a director of the Company, participated in the Offering. Pursuant to MI 61-101, the Company will file a material change report providing disclosure in relation to each "related party transaction" on SEDAR+ under the Company's issuer profile at The Company did not file the material change report more than 21 days before the expected closing date of the Offering as the details of the Offering were not settled until shortly prior to the conclusion of the Offering, and the Company wished to complete the Offering on an expedited basis for sound business reasons. The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements available under MI 61-101. The Company is exempt from the formal valuation requirement in section 5.4 of MI 61-101 in reliance on sections 5.5(a) and (b) of MI 61-101 as the fair market value of the transaction, insofar as it involves each of the significant shareholders, is not more than 25% of the Company's market capitalization. Additionally, the Company is exempt from minority shareholder approval requirement in section 5.6 of MI 61-101 in reliance on section 5.7(1)(a) as the fair market value of the transaction, insofar as it involves each of the significant shareholders, is not more than 25% of the Company's market capitalization. The Offering was previously approved by the board of directors of the Company, including disinterested directors. No special committee was established in connection with the transaction, and no materially contrary view was expressed or made by any director. No finder's fee was paid in this Offering. The Common Shares and Warrants issued under the Offering will be subject to a statutory hold period expiring four months and one day from the date of issuance or longer for certain subscribers. The Offering remains subject to final approval of the TSX Venture Exchange. The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful. Fairchild intends to use the net proceeds of the Offering for geophysical surveys and expanded field work at the Company's Project in Nevada, as well as marketing and general working capital purposes. About Fairchild Gold Corp. Fairchild Gold Corp. is a mineral exploration company focused on acquiring, exploring, and developing high-quality mineral properties in mining-friendly jurisdictions. The Company's flagship Nevada Titan Project is in the historic Goodsprings mining district in Nevada, USA. The Company is also the 100% owner of the Fairchild Lake Property consisting of 108 mining claims covering an area of 2,224 hectares, located approximately 250 kilometres northwest of the city of Thunder Bay in the Patricia Mining Division, Ontario. On behalf of the Board of Directors Luis MartinsDirector and Chief Executive OfficerFairchild Gold Neither the TSX Venture Exchange nor its Regulation Services Provider (as the term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this news release. Cautionary Statement Regarding Forward-Looking Information Certain information contained in this news release constitutes "forward-looking information" or "forward-looking statements" (collectively, "forward- looking information"). Without limiting the foregoing, such forward-looking information includes statements regarding the process and completion of the Offering, the use of proceeds of the Offering and any statements regarding the Company's business plans, expectations and objectives. In this news release, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking information. Forward-looking information should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking information is based on information available at the time and/or the Company management's good faith belief with respect to future events and is subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. For additional information with respect to these and other factors and assumptions underlying the forward-looking information made in this news release, see the Company's most recent Management's Discussion and Analysis and financial statements and other documents filed by the Company with the Canadian securities commissions and the discussion of risk factors set out therein. Such documents are available at under the Company's profile and on the Company's website, The forward-looking information set forth herein reflects the Company's expectations as at the date of this news release and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 days ago
- Yahoo
Sylla Gold Announces Loans
Bedford, Nova Scotia--(Newsfile Corp. - June 6, 2025) - Sylla Gold Corp. (TSXV: SYG) (OTC Pink: SYGCF) ("Sylla" or the "Company") announces it has issued unsecured promissory notes (the "Notes") in the principal amount of $45,000 in connection with the loans (the "Loans") to the Company from non arm's length and arm's length lenders (collectively, the "Lenders"). The Notes bear interest at seven percent (7%) per annum and the Loans and any accrued interest owing pursuant to the Notes, shall become due and be paid in full on demand, which demand may be made by the Creditor at any time after June 6, 2026. In connection with the Notes, the Company will issue to the Lenders an aggregate of 599,998 common shares (each, a "Common Share") in the capital of the Company at a deemed price of $0.015 per Common Share as a loan bonus. The Company intends to use the net proceeds from the Loans for: (i) approximately $36,000 for the audit for the financial year ended February 28, 2024; (ii) approximately $4,000 to the Company's transfer agent, for services rendered; and (iii) approximately $5,000 for general working capital purposes. All Common Shares issued in connection with the Notes will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. The issuance of the Common Shares remains subject to receipt of all necessary corporate and regulatory approvals, including the approval of the TSX Venture Exchange. The issuance of the Notes constitutes a related party transaction within the meaning of TSX Venture Exchange Policy 5.9 and Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") as certain Lenders are directors and/or officers of the Company. The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(b) and 5.7(1)(a) of MI 61-101, as the Company is not listed on a specified market and the principal amount of the Notes held by the insiders do not exceed 25% of the market capitalization of the Company in accordance with MI 61-101. The Company did not file a material change report more than 21 days before the issuance of the Notes as the Company wished to close on an expedited basis. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons as defined under applicable United States securities laws unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. For more information, please contact: Regan IsenorPresident and Chief Executive OfficerTel: (902) 233-4381Email: risenor@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains certain "forward-looking information" within the meaning of applicable securities laws. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) ('Rakovina' or the 'Company'), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the closing of its previously announced non-brokered private placement for gross proceeds of $4,905,150 - consisting of $3,555,150 of Units and $1,350,000 of Debenture Units (each as defined below). The private placement consists of a combination of equity units (the 'Units') and convertible debenture units (the 'Debenture Units'), issued at a price of $0.05 per Unit and $50,000 per Debenture Unit. Each Unit includes one common share of the Company (a 'Common Share') and one Common Share purchase warrant (a 'Warrant'). Each Warrant entitles the holder to purchase one additional Common Share at a price of $0.10 for a period of 24 months following the date of issuance, subject to acceleration in certain scenarios and customary adjustments. Each Debenture Unit is comprised of one unsecured convertible debenture (a 'Debenture') in the principal amount of $50,000 and 100,000 Common Share purchase warrants (the 'Debenture Warrants'). Each Debenture Warrant will entitle the holder to purchase one additional Common Share at a price of $0.15 for a period of 24 months from issuance, subject to customary adjustments. The principal amount of each Debenture shall be repayable in 36 months from issuance (unless earlier converted or redeemed) and will accrue interest at a rate of 12% per annum. Until the principal amount is repaid, a Debenture holder shall have the option to convert the principal amount of the Debenture into Common Shares at a conversion price of $0.10 per Common Share, subject to customary adjustments, including adjustment upon completion of the proposed Consolidation (as defined below). Rakovina shall be entitled to redeem all or a portion of the principal amount of each Debenture at any time commencing 12 months after issuance of such Debenture, in cash and without premium. In connection with the private placement, Rakovina paid cash finder's fees to Canaccord Genuity Corp., Ventum Financial Corp., Haywood Securities Inc., and Leede Financial Inc., totaling $ $60,035.50, and issued 1,200,710 non-transferable finder's warrants (each, a 'Finder's Warrant'). Each Finder's Warrant entitles the holder to purchase one Common Share at $0.10 for a period of 24 months, subject to acceleration on the same terms as the Warrants. Certain insiders of the Company subscribed for an aggregate of 14,700,000 Units for aggregate gross proceeds to the Company of $735,000. The issuance of such Units constitutes a related party transaction under Multilateral Instrument 61-101 – Protection of Minority Security Holders in special Transactions ('MI 61-101') and Policy 5.9 by the TSX Venture Exchange ('TSXV'). The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements under MI 61-101 on the basis that neither the fair market value of the Units issued to interested parties (as defined in MI 61-101), nor the consideration received for those Units, exceeds 25% of the Company's market capitalization. No new insiders were created, nor has there been a Change of Control (as defined in TSXV Policies) as a result of closing the private placement. The Company did not file a material change report more than 21 days before the closing date, as the details and amounts of insider participation was not finalized until shortly prior to the closing date. All securities issued in connection with the private placement are subject to a statutory hold period of four months and one day in accordance with applicable securities laws. The Company previously announced it intends to implement a 10-for-1 share consolidation (the 'Consolidation') following closing of the private placement. The amounts set out above in respect of the private placement are all presented on a pre-Consolidation basis and will be adjusted following closing of the private placement upon completion of the Consolidation. The private placement and Consolidation are subject to final acceptance by the TSXV. 'We're pleased with the strong support from both existing and new shareholders,' said Jeff Bacha, Executive Chairman of Rakovina Therapeutics. 'This financing is a pivotal step in Rakovina's evolution. It not only provides the capital to advance our development plans but also strengthens our position as we align with prospective partners and U.S. investors for the next phase of growth.' Use of Proceeds Proceeds from the financing are intended to support Rakovina Therapeutics' growth across multiple fronts, including the continued integration of its proprietary next-generation AI-driven drug discovery tools, and the efforts to expand visibility among institutional investors in U.S. and global capital markets. IR and Marketing Collaborations Rakovina also announces the continued engagement of Fairfax Partners Inc. ('Fairfax') as its Investor Relations ('IR') partner and a new engagement of Machai Capital Inc. ('Machai') to provide corporate communication services. Fairfax will implement a comprehensive three-month IR program which will continue to build on Rakovina's market presence with a goal to increase its investor base. The program, which includes an option to renew, focuses on complementing traditional IR efforts with targeted online marketing campaigns, activation of a robust social media influencer network, and collaboration with external consultants and global wealth management channels. Under the terms of the agreement, Fairfax will receive an initial fee of $250,000 (plus GST), payable upon execution of the agreement. This amount will cover the first three months of marketing execution, with Fairfax retaining a 20% service fee on all marketing funds allocated. At its sole discretion, the Company may allocate up to an additional $200,000 to extend the campaign for an additional three-month term. Machai Capital will utilize its expertise in branding, content and data optimization, search engine optimization, search engine marketing, lead generation, digital marketing, social media marketing, email marketing, and brand marketing to enhance the Company's marketing campaigns and increase awareness of the Company. The Company will provide Machai Capital with a marketing budget of $250,000 (plus GST), payable upon entry into the agreement. As of the date hereof, the directors and officers of Machai Capital do not own any securities of the Company. Machai Capital and its principals have an arm's length relationship with the Company. About Machai Capital Machai Capital provides services in branding, content and data optimization, search engine optimization, search engine marketing, lead generation, digital marketing, social media marketing, email marketing, and brand marketing to enhance its client marketing campaigns and awareness. Machai Capital's head office is located in Vancouver, British Columbia. About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed Consolidation, the use of proceeds from the private placement, the business plan of the company, the Company's growth across multiple fronts and other prospective statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed, except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact: Michelle Seltenrich, BSc, MBADirector, Corporate DevelopmentIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
